Marinus Pharmaceuticals, Inc.
(NASDAQ GM: MRNS)
Rigrodsky Law, P.A. is investigating Marinus Pharmaceuticals, Inc. (“Marinus”) regarding possible breaches of fiduciary duties and other violations of law related to Marinus’ agreement to be acquired by Immedica Pharma AB. Under the terms of the agreement, Marinus shareholders will receive $0.55 per share in cash.